SCHEMBL4898439

SCHEMBL4898439

N#Cc1c(Cl)nc(NC2CC2)nc1-c1ccc(F)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 4/20 0.52
▸ BRAF P15056 1/20 0.46
▸ ADORA1 P30542 5/20 0.39
▸ ADORA2A P29274 2/20 0.38
▸ CTSV O60911 2/20 0.38
▸ PLAT P00750 2/20 0.38
▸ CTSL P07711 2/20 0.38
▸ CTSH P09668 2/20 0.38
▸ CTSS P25774 2/20 0.38
▸ CASP14 P31944 2/20 0.38
▸ CTSK P43235 2/20 0.38
▸ CASP6 P55212 2/20 0.38
▸ CTSZ Q9UBR2 2/20 0.38
▸ ACHE P22303 1/20 0.37
▸ MCHR1 Q99705 1/20 0.36
▸ ADORA2B P29275 1/20 0.36
▸ IDH1 O75874 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4899212 0.86 KDM1A (0.47) KDM1AADORA1ADORA2ACTSVPLAT
SCHEMBL4909018 0.84 ADORA1 (0.56) ADORA1ADORA2ACTSVPLATCTSL
SCHEMBL4907249 0.83 KMT2A (0.41) KDM1ABRAFADORA1ADORA2ACTSV
SCHEMBL4906255 0.83 ADORA1 (0.47) ADORA1ADORA2ACTSVPLATCTSL
SCHEMBL4906201 0.81 KMT2A (0.55) KDM1AADORA1ADORA2AACHEADORA2B
SCHEMBL4899380 0.81 ADORA1 (0.53) ADORA1ADORA2ACTSVPLATCTSL
SCHEMBL4911779 0.81 CTSK (0.40) ADORA1ADORA2ACTSVPLATCTSL
SCHEMBL4907303 0.81 CTSS (0.47) KDM1AADORA1ADORA2ACTSSCTSK
SCHEMBL4906676 0.81 ACHE (0.43) ADORA1ADORA2ACTSVPLATCTSL
SCHEMBL4909514 0.80 ADORA1 (0.50) ADORA1ADORA2ACTSVPLATCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 — — EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 — — US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF KDM1A 3031/4885BRAF 3/4885ADORA1 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback